Filing Details

Accession Number:
0001401708-21-000116
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2021-04-13 19:51:06
Reporting Period:
2021-03-15
Accepted Time:
2021-04-13 19:51:06
Original Submission Date:
2021-03-17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1401708 Nanostring Technologies Inc NSTG Biological Products, (No Disgnostic Substances) (2836) 200094687
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1710720 Chad J. Brown 530 Fairview Avenue N
Seattle WA 98109
Svp, Sales & Marketing No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-15 5,376 $0.00 11,037 No 4 A Direct
Common Stock Disposition 2021-03-16 1,335 $66.32 9,702 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
  2. On March 17, 2021, the Reporting Person filed a Form 4 which inadvertently misstated the number of shares held by the Reporting Person following the vesting of 5,376 RSUs reported on the Form 4. The number of shares reported in Column 5 of this Form 4/A reflects the corrected amount of securities beneficially owned by the Reporting Person following the vesting of such RSUs on March 15, 2021.
  3. The reported shares were sold to cover the reporting person's tax liability in connection with the vesting of RSUs.
  4. On March 17, 2021, the Reporting Person filed a Form 4 which (i) inadvertently misstated the date of a sale of shares to cover the Reporting Person's tax liability in connection with the vesting of the RSUs, (ii) included an incorrect Transaction Code in Column 3 of the Form 4 in relation to said sale, and (iii) in Column 5, inadvertently misstated the number of shares held by the Reporting Person following the sale of shares reported in the Form 4. The Date reported in Column 2 of this Form 4, the Amount reported in Column 5 of this Form 4/A, and reflect corrections to these items.